Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck's Appeal In Vioxx Case Likely To Focus On Expert Testimony, Evidentiary Rulings

This article was originally published in The Pink Sheet Daily

Executive Summary

In the first Vioxx product liability case to reach trial, a Texas jury awards the plaintiff $253.5 mil. in damages, the bulk of which are punitive damages that would be capped under state law.

You may also be interested in...



Win, Lose & Draw: Third Merck Vioxx Trial Ends In Mistrial

A Houston jury was unable to reach a verdict in the first federal product liability trial over the COX-2 inhibitor.

Win, Lose & Draw: Third Merck Vioxx Trial Ends In Mistrial

A Houston jury was unable to reach a verdict in the first federal product liability trial over the COX-2 inhibitor.

Merck Cleared In Second Vioxx Product Liability Case

Atlantic City, N.J. state court verdict clears Merck of allegations the drug maker failed to warn patients of risks associated with the use of Vioxx.

Related Content

Topics

UsernamePublicRestriction

Register

OM006922

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel